ORGANIC
LETTERS
2011
Vol. 13, No. 1
86-89
Enantioselective Synthesis of A Key
A-Ring Intermediate for the Preparation
of 1r,25-Dihydroxyvitamin D3
Yan Chen* and Tong Ju
Tianjin Key Laboratory for Modern Drug DeliVery & High-Efficiency, School of
Pharmaceutical Science and Technology, Tianjin UniVersity, Tianjin 300072, China
Received October 27, 2010
ABSTRACT
A novel approach to the key A-ring r, ꢀ-unsaturated aldehyde 1, an important intermediate for the preparation of 1r,25-dihydroxyvitamin D3,
has been developed. The strategy started from the inexpensive starting material (R)-carvone with an ene reaction serving as the key step
toward the potential synthesis of vitamin D3 analogues bearing the modification at the C-2 position.
1R,25-Dihydroxyvitamin D3 (calcitriol), the active form of
vitamin D3, is a multifunctional steroidal hormone that
regulates cell differentiation, cell proliferation, and the
immune system, in addition to its classical function in
calcium and phosphate metabolism.1 However, therapeutic
utility of calcitriol in the treatment of cancer and psoriasis
is limited by its potent calcemic effects.2 Thus, the research
for noncalcemic therapeutic agents and for convenient
methods of synthesizing modified calcitriol has been greatly
stimulated by medical needs. It is not surprising that more
than 3000 vitamin D3 analogues have been synthesized over
the past few decades.3 However, most of these synthetic
studies involved side-chain modification and the decoration
of the A-ring is not intensively reported.4 Therefore, the
construction of building blocks that could lead to vitamin
D3 analogues bearing the modification on the A-ring is of
important significance.
The R,ꢀ-unsaturated aldehyde 1 is an essential building
block for the synthesis of 1R,25-dihydroxyvitamin D3 in
Julia’s olefination approach5 (Figure 1). And in the enyne
approach,6 1 is a key intermediate which could furnish
the A-ring 3 by Corey-Fuchs homologation.7 Although the
majority of the syntheses of 1 utilized (S)-carvone as the
starting material,8 application of (R)-carvone remains unex-
ploited despite the obvious cost advantage over its enanti-
(3) (a) Zhu, G. D.; Okamura, W. H. Chem. ReV. 1995, 95, 1877–1952.
(b) Dai, H.; Posner, G. H. Synthesis 1994, 1383–1398. (c) Mathieu, C.;
Adorini, L. Trends Mol. Med. 2002, 8, 174–179. (d) Nagpal, S.; Na, S.;
Rathnachalam, R. Endocr. ReV. 2005, 26, 662–687. (e) Laverny, G.; Penna,
G.; Uskokvic, M.; Marczak, S.; Maehr, H.; Jankowski, P.; Ceailles, C.;
Vouros, P.; Smith, B.; Robinson, M.; Reddy, G. S.; Adorini, L. J. Med.
Chem. 2009, 52, 2204–2213. (f) Nakabayashi, M.; Yamada, S.; Yoshimoto,
N.; Tanaka, T.; Igarashi, M.; Ikura, T.; Ito, N.; Makishima, M.; Tokiwa,
H.; DeLuca, H. F.; Shimizu, M. J. Med. Chem. 2008, 51, 5320–5329.
(4) (a) Norman, A. W.; Ishizuka, S.; Okamura, W. H. J. Steroid.
Biochem. Mol. Biol. 2001, 76, 49–59. (b) Sicinski, R. R.; Rotkiewicz, P.;
Kolinski, A.; Sicinska, W.; Prahl, J. M. J. Med. Chem. 2002, 45, 3366–
3380. (c) Saito, N.; Suhara, Y.; Kurihara, M.; Fijishima, T.; Honzawa, S.;
Takayanagi, H.; Kozono, T.; Matsumoto, M.; Ohmori, M.; Miyata, N.;
Takayama, H.; Kittaka, A. J. Org. Chem. 2004, 69, 7463–7471. (d)
Glebocka, A.; Sicinski, R.; Plum, L. L.; Clagett-Dame, M.; DeLuca, H. F.
J. Med. Chem. 2006, 49, 2909–2920. (e) Sicinskil, R. R.; Glebocka, A.;
Plum, L. A.; Deluca, H. F. J. Med. Chem. 2007, 50, 6154–6164.
(5) Kocienski, P. J.; Lythgoe, B.; Ruston, S. J. Chem. Soc., Perkin Trans.
1 1980, 1400–1404.
(1) (a) Feldman, D., Pike, J. W., Glorieux, F. H., Eds. Vitamin D, 2nd
ed.; Elsevier Academic Press: New York, 2005. (b) DeLuca, H. F. Nutr.
ReV. 2008, 66, s73–s87. (c) Adorini, L.; Penna, G. Nat. Clin. Pract.
Rheumatol. 2008, 4, 404–412. (d) White, P.; Cooke, N. Trends Endocrinol.
Metab. 2000, 11, 320–327. (e) Hammes, S. R. Proc. Natl. Acad. Sci. U.S.A.
2003, 100, 21680–21700. (f) Holick, M. F., Eds. Vitamin D; Humana Press:
Totowa, NJ, 1999.
(2) (a) Bouillon, R.; Okamura, W. H.; Norman, A. W. Endocr. ReV.
1995, 16, 200–257. (b) Carlberg, C.; Mourin´o, A. Expert Opin. Ther. Patents
2003, 13, 761–772. (c) DeLuca, H. F. J. Bone Miner. Metab. 1990, 8, 1–9.
(d) Bexkman, M. J.; DeLuca, H. F. Prog. Med. Chem. 1998, 35, 1–56. (e)
Stein, M. S.; Wark, J. D. Expert Opin. InVestig. Drugs 2003, 12, 825–840.
10.1021/ol102586w 2011 American Chemical Society
Published on Web 12/06/2010